NICE Final Guidance for AGAMREE (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy Is Positive for Santhera AGAMREE (vamorolone) has been recommended for use in the National Health Service (NHS) in England, Wales, and Northern Ireland for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 and up by the National Institute for Health and Care Excellence (NICE), according to Santhera Pharmaceuticals.

NICE Final Guidance for AGAMREE (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy Is Positive for Santhera

👉 Read More: dmdwarrior.com

#dmd #duchenne #dmdwarrior #dmdwarriors #duchennesmusculardystrophy #agamree #vamorolone #santhera #NICE #uk #england #wales #northernireland

Vamorolone (Agamree) Approved in Scotland The Scottish Medicines Consortium (SMC) approved the Agamree (Vamorolone) for use by NHS Scotland. The medication vamorolone, also marketed under the brand name Agamree, has been approved by the Scottish Medicines Consortium (SMC) as a therapy option for Duchenne muscular dystrophy in patients four years of age and older in Scotland as of today, Monday, January 13 2025.

Vamorolone (Agamree) Approved in Scotland

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenneawareness #duchenneheroes #musculardystrophy #gene #dna #agamree #vamorolone #santhera #scotland #uk #england

Santhera Enters into Supply and Distribution Agreement for AGAMREE (Vamorolone) with Clinigen Group "We look forward to working with Santhera to make AGAMREE available to patients globally on an unlicensed basis in those territories where it is not currently licensed or reimbursed. ” said Julie Gosper, Senior Vice President, Europe and Partner Markets at Clinigen. Santhera Pharmaceuticals announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® (vamorolone) in countries where the product is not otherwise commercially available. Santhera Pharmaceuticals and Clinigen Group announce that they have signed a Supply and Distribution Agreement for AGAMREE in countries where the product can currently not be commercially obtained via Santhera or one of its current distribution partners. The agreement will enable access to AGAMREE on a case-by-case basis for patients with Duchenne muscular dystrophy (DMD) in situations where the treating physician deems there to be no suitable alternatives and where regulations allow for it. This agreement allows Santhera to receive the majority share of revenue generated from the supply of product in these additional countries.

Santhera Enters into Supply and Distribution Agreement for AGAMREE (Vamorolone) with Clinigen Group

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenne #agamree #vamorolone #santhera #Clinigen #clinigengroup

Agamree recommended for NHS use in England

Agamree recommended for NHS use in England

Agamree recommended for NHS use in England

Agamree recommended for NHS use in England

Agamree recommended for NHS use in England 🎉

Elsewhere, Agamree was approved in China, making it the country’s first treatment for DMD.

#dmd #duchenne #bmd #becker #santhera #agamree #uk #vamorolone #england

Santhera Announces Approval from China’s NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy

Santhera Announces Approval from China’s NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy

Santhera Announces Approval from China’s NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy

Santhera Announces Approval from China’s NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy

Santhera Announces Approval from China’s NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy 🎉

Source: www.santhera.com/assets/files...

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #santhera #agamree #china #vamorolone